gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ADPTHealthcareBiotechnology

Adaptive Biotechnologies Corporation Common Stock (ADPT)

$26.71+3.53%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$26.71▲ 57.86% in range
Nov 4, 2025Low $12.41 · High $29.84Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Adaptive Biotechnologies closed at $26.71 on Nov 4, up 3.53%, 10.5% below its 52-week closing high. Volume of 2.3M shares was 1.17× its 20-day average (close to normal).

Split-adjusted performance: -0.7% over one month, +85.1% over six months, +54.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $71.55M, up 21.5% from a year earlier, with a net margin of -55.6%.

Short interest was 12.0M shares at the Oct 15 settlement, up 1.3% from the prior report (10.0% of float, 5.0 days to cover).

Market cap$4.26B159.6M shares
Revenue · quarter$71.6M+21.5% YoY
Diluted EPS$-0.25—
P/E · TTM—P/S 13.8×
Net margin-55.6%Gross 71.8%
Dividend yieldNone
52-week range12.41 – 29.84−10.5% from high
Volume2.3M1.17× 20-day avg
Volatility · 60d51.6%Annualised
Short % of float10.0%5.0 days to cover
Net cash$9.4MCash $344.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −5.9%1M −0.7%3M +13.2%6M +85.1%YTD +64.5%1Y +54.0%3Y +516.9%5Y −17.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum94
Revenue growth63
Net margin64
Value (low P/E)—
Size86

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short12.0M+1.3% vs prior
Days to cover5.0Settled Oct 15
% of float10.0%
Short vol. 10d46.4%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ADPTAdaptive Biotechnologies$26.71+3.53%+85.1%+21.5%−55.6%—$4.26B
RLAYRelay Therapeutics$18.03+3.38%+39.6%−48.3%−23916.3%—$3.95BCompare
IOVAIovance Biotherapeutics$8.70−1.47%+112.7%+65.7%−47.6%—$3.94BCompare
CRSPCRISPR Therapeutics AG$51.78+3.57%−6.0%+1325.1%−879.6%—$5.01BCompare
DNLIDenali Therapeutics$20.96+7.76%+2.7%—−3539.2%—$3.35BCompare
SRRKScholar Rock Holding$46.09+4.80%−2.2%———$5.61BCompare
TARSTarsus Pharmaceuticals$69.07−4.91%+6.7%+63.9%−343.5%—$3.23BCompare
CGONCG Oncology$67.71+5.70%−0.4%—−6832.8%—$6.00BCompare
IMVTImmunovant$29.90+2.96%+4.3%———$6.18BCompare

News about Adaptive Biotechnologies

All news →
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% RunThe Motley Fool · Jul 12, 2026▲ PositiveAdaptive Biotechnologies Business Separation May Unlock Greater ValueBenzinga · Jun 17, 2026NeutralAdaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes OfferingGlobeNewswire Inc. · Jun 17, 2026NeutralAdaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine BusinessesBenzinga · Jun 16, 2026▲ PositiveWhat Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?The Motley Fool · Jun 14, 2026Neutral

Quick answers

What does Adaptive Biotechnologies do?
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers.
What is ADPT's market cap?
$4.26B, based on the Nov 4 close of $26.71.
Does Adaptive Biotechnologies pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ADPT is sold short?
12.0M shares, 10.0% of float, as of Oct 15, 2026.
What sector is ADPT in?
Healthcare, in the Biotechnology industry.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

HQ: Seattle, WA624 employeesListed Jun 27, 2019adaptivebiotech.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology